PRC
ASMB icon

Pearl River Capital’s Assembly Biosciences ASMB Stock Holding History

Pearl River Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-67
Closed -$16K – 271
2019
Q1 		$16K Sell
67
-1
-1% -$253 0.04% 295
2018
Q4 		$19K Buy
+68
New +$19.7K 0.09% 305

Other funds holding ASMB

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Pearl River Capital's ASMB Position: Q2 2019 in Review

Pearl River Capital sold out of Assembly Biosciences (ASMB) in Q2 2019, closing a stake of 67 shares — an estimated $16K sold.

Pearl River Capital first reported a position in ASMB in Q4 2018 and held it in 2 quarters. The position peaked at $19K in Q4 2018. 106 funds tracked by Wall St. Rank hold ASMB as of Q2 2019.

  • Pearl River Capital reported no remaining Assembly Biosciences position as of Q2 2019 after selling out during the quarter.
  • Pearl River Capital sold 67 Assembly Biosciences shares in Q2 2019, an estimated $16K.
  • Pearl River Capital first reported a position in Assembly Biosciences in Q4 2018 and held it in 2 quarters.
  • Pearl River Capital's Assembly Biosciences position peaked at $19K in Q4 2018.
  • 106 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2019.

Based on Pearl River Capital's 13F filing for Q2 2019, filed 12 Aug 2019.